Loading...

Trevor Angell

TitleAssistant Professor of Clinical Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressBMT B11
Off Campus
Los Angeles CA 90089-9113
Phone+1 323 442 6179
vCardDownload vCard
    Other Positions
    TitleAssociate Medical Director of Thyroid Center


    Collapse Overview 
    Collapse Overview
    Trevor E Angell, MD is an Assistant Professor of clinical medicine in the Department of Medicine’s division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC.

    Dr. Angell is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests are related to the diagnosis and treatment of thyroid diseases. He has receiving funding for his research predicting thyroid cancer in patients with thyroid nodules from the Thyroid Cancer Survivors' Association (American Thyroid Association Research Grant) and Harvard Medical School scholars in medicine program.

    He has published articles in JAMA Surgery, Thyroid, The Journal of Clinical Endocrinology and Metabolism, and Current Opinion in Endocrinology and Diabetes, including original research and invited reviews. He is on the editorial board of Frontiers in Endocrinology and is a member of the Endocrine Society and the American Thyroid Association where he serves as the Co-Chair of the Patient Affairs and Education Committee.

    After finishing his clinical and research training at the Keck School of Medicine and the Los Angeles County-USC Medical Center, Dr. Angell went to work as an instructor in medicine and the Brigham and Women’s Hospital and Harvard Medical School in 2014 performing patient care, residents and fellow teaching, and research. Dr. Angell is recognized for clinical expertise in thyroid nodules, thyroid cancer, thyroid hormone dysfunction, and thyroid disorders during pregnancy. He is nationally known for research into thyroid nodule evaluation and molecular testing of thyroid nodules. In 2018, Dr. Angell joined the faculty at the Keck School of Medicine.


    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cherella CE, Feldman HA, Hollowell M, Richman DM, Cibas ES, Smith JR, Angell T, Wang Z, Alexander EK, Wassner AJ. Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children. J Clin Endocrinol Metab. 2018 Jul 02. PMID: 29982665.
      View in: PubMed
    2. Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg. 2018 May 23. PMID: 29799911.
      View in: PubMed
    3. Angell TE, Van Benschoten O, Cohen DA, Haas AV, Alexander EK, Marqusee E. POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS. Endocr Pract. 2018 Apr 06. PMID: 29624097.
      View in: PubMed
    4. Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE. Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients =70 Years Old. Thyroid. 2018 Apr; 28(4):465-471. PMID: 29608439.
      View in: PubMed
    5. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid. 2018 Apr; 28(4):445-453. PMID: 29652597.
      View in: PubMed
    6. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid. 2018 Apr; 28(4):437-444. PMID: 29652599.
      View in: PubMed
    7. Angell TE, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD, Nehs MA. Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. Ann Surg Oncol. 2018 May; 25(5):1410-1417. PMID: 29520656.
      View in: PubMed
    8. Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA. Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Endocr Pathol. 2018 Mar; 29(1):68-74. PMID: 29396809.
      View in: PubMed
    9. Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD, Nehs MA, Zavacki AM, Larsen PR, Alexander EK. Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. J Clin Endocrinol Metab. 2017 Dec 01; 102(12):4642-4647. PMID: 29040691.
      View in: PubMed
    10. Angell TE, Min L, Wieczorek TJ, Hodi FS. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis. 2018 Mar; 5(1):46-48. PMID: 29619406.
      View in: PubMed
    11. Angell TE. RAS-positive thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2017 Oct; 24(5):372-376. PMID: 28639967.
      View in: PubMed
    12. Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF. A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience. Cancer Cytopathol. 2017 Nov; 125(11):854-864. PMID: 28902465.
      View in: PubMed
    13. Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. Endocr Pathol. 2017 Jun; 28(2):171-176. PMID: 28271380.
      View in: PubMed
    14. Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations. Thyroid. 2017 04; 27(4):506-511. PMID: 28114855.
      View in: PubMed
    15. Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell TE. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol. 2017 05; 125(5):313-322. PMID: 28152275.
      View in: PubMed
    16. Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK. Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4938-4944. PMID: 27689252.
      View in: PubMed
    17. Wong KS, Angell TE, Strickland KC, Alexander EK, Cibas ES, Krane JF, Barletta JA. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. Thyroid. 2016 07; 26(7):911-5. PMID: 27219469.
      View in: PubMed
    18. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. PMID: 26756227; PMCID: PMC4790214 [Available on 03/01/17].
    19. Medici M, Liu X, Kwong N, Angell TE, Marqusee E, Kim MI, Alexander EK. Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study. BMC Med. 2016 Jan 27; 14:11. PMID: 26817603; PMCID: PMC4730757.
    20. Minkovsky A, Lee MN, Dowlatshahi M, Angell TE, Mahrokhian LS, Petrides AK, Melanson SE, Marqusee E, Woodmansee WW. HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. AACE Clin Case Rep. 2016; 2(4):e370-e373. PMID: 27917400.
      View in: PubMed
    21. Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT, Gawande A, Moore F, Barletta J, Krane JF, Cibas ES, Yang T, Alexander EK. Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. Thyroid. 2016 Feb; 26(2):256-61. PMID: 26563459; PMCID: PMC4754507 [Available on 02/01/17].
    22. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR, Alexander EK. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab. 2015 Dec; 100(12):4434-40. PMID: 26465395.
      View in: PubMed
    23. Angell TE, Frates MC, Medici M, Liu X, Kwong N, Cibas ES, Kim MI, Marqusee E. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up. J Clin Endocrinol Metab. 2015 Nov; 100(11):E1477-83. PMID: 26353010; PMCID: PMC4702458 [Available on 11/01/16].
    24. Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD, Alexander EK. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015 Aug 07; 13:184. PMID: 26253102; PMCID: PMC4528713.
    25. Angell TE, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S. Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015 Sep; 94(9):1603-4. PMID: 26048244.
      View in: PubMed
    26. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. PMID: 25343237.
      View in: PubMed
    27. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906; PMCID: PMC4252612.
    28. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518; PMCID: PMC4148060.
    29. Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. PMID: 24697314.
      View in: PubMed